Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206069 | 0.86 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL14509630 | 0.86 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL1831560 | 0.86 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL13472620 | 0.85 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL8470821 | 0.85 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL8255716 | 0.84 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL13853654 | 0.83 | ALDH1A1 (0.75) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL13853692 | 0.83 | ALDH1A1 (0.75) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL26999887 | 0.83 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL12788564 | 0.82 | ALDH1A1 (0.64) | ALDH1A1L3MBTL1HTTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | ALDH1A1 392/4885L3MBTL1 2097/4885HTT 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.